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Background
Available display systems allow screening of proteins out
of millions of candidates and are the method of choice to
identify optimized antigen-antibody binding. While
phage display libraries are used for polypeptides like scFv
antibodies, eukaryotic display platforms were developed
to overcome the limitations of prokaryotic expression and
presentation. We established a mammalian cell-surface
display to present HIV-1 envelope derivatives in a natural,
trimeric, membrane bound environment to generate
affinity enhanced envelope derivatives against broad neu-
tralizing antibodies (bNAb), with the objective of select-
ing potent envelope (Env) based vaccine candidates.
Methods
HEK 293T cells were infected with a pseudotyped HIV-1
Env library, providing different envelope derivatives.
Enrichment of cells displaying envelopes, with high affin-
ity to bNAb was achieved by cell separation. After elution
of affinity enriched cells, the envelope genes were ampli-
fied and cloned back into a lentiviral vector to enter a new
round of selection. Best binders were enriched by iterative
rounds of selection.
Results
A specific enrichment of envelopes with higher affinities
to the applied antibody was achieved as measured by
FACS analysis and DNA sequencing of the selected clones.
Screening clones after every panning cycle reflects the
progress of the enrichment process.
Conclusion
With the method described we show that mammalian
cell-surface display of HIV-1 envelopes is feasible to
enrich envelope derivatives with higher affinity to the
applied antibody. By using bNAbs for selection of enve-
lopes out of different libraries new candidates for the
potential use in HIV vaccine trials can be identified.
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